Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 6/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | TGM2 | P21980 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665297 | 0.91 | MAPK3 (0.49) | MAPK3FGFR4BRAFKDR | |
| SCHEMBL16665334 | 0.88 | GCK (0.54) | MAPK3FGFR4TGM2FGFR2FGFR3 | |
| SCHEMBL16665246 | 0.86 | FGFR4 (0.56) | MAPK3FGFR4TGM2FGFR2FGFR3 | |
| SCHEMBL16665247 | 0.86 | FGFR4 (0.48) | MAPK3FGFR4TGM2FGFR2FGFR3 | |
| SCHEMBL16665304 | 0.83 | BTK (0.47) | MAPK3FGFR4FGFR2FGFR3FGFR1 | |
| SCHEMBL16665335 | 0.82 | FGFR4 (0.59) | MAPK3FGFR4FGFR2FGFR3FGFR1 | |
| SCHEMBL16665295 | 0.82 | FGFR4 (0.50) | MAPK3FGFR4FGFR2FGFR3FGFR1 | |
| SCHEMBL16665336 | 0.81 | FGFR4 (0.55) | MAPK3FGFR4FGFR2FGFR3FGFR1 | |
| SCHEMBL16665312 | 0.81 | EGFR (0.43) | MAPK3FGFR4TGM2FGFR2FGFR3 | |
| SCHEMBL16665339 | 0.80 | FGFR4 (0.44) | MAPK3FGFR4BRAFKDRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |